Zimmer Biomet Lifts 2026 Organic Sales Outlook To 3.0%-3.5% As Knee Sales Fall 2.6%

Hips, bone cement and surgical products grew in the third quarter while knees declined, and adjusted EPS guidance narrowed to $8.50 to $8.60.

Share
Zimmer Biomet Lifts 2026 Organic Sales Outlook To 3.0%-3.5% As Knee Sales Fall 2.6%

Zimmer Biomet, the orthopedic device maker, raised its 2026 organic sales growth forecast to 3.0% to 3.5% from 2.25% to 3.25%, as third-quarter net sales of $2.063 billion rose 3.7% at constant currency. The company reported the results in an 8-K filed Wednesday.

Hips and surgical lines offset knees

Reported sales grew 3.1%. Hips rose 7.0% at constant currency, the technology and data, bone cement and surgical group climbed 13.0%, and the sports medicine and related group (S.E.T.) rose 7.1%. Knees fell 2.6%.

CEO Ivan Tornos said hips, S.E.T. and the technology group, which he put at two-thirds of the company's book of business, grew at upper single-digit or double-digit rates. He said that gave management "confidence to raise our full-year organic constant-currency sales growth and adjusted EPS guidance."

Profit slips as adjusted EPS holds

Diluted earnings per share fell 13.8% to $1.00. Adjusted earnings per share were $1.90, matching the prior-year quarter. Net earnings were $191.6 million, or $362.8 million on an adjusted basis.

Operating profit margin fell to 14.9% from 17.6% a year earlier. Zimmer Biomet generated $560.0 million of operating cash flow and $372.4 million of free cash flow in the quarter.

The updated 2026 guidance

Zimmer Biomet, which makes knee and hip replacements, sports medicine products and robotic surgery systems, narrowed adjusted EPS guidance to $8.50 to $8.60 from $8.47 to $8.59. Reported revenue growth is now projected at 4.4% to 4.9%, up from 3.9% to 4.9%. Constant-currency growth is projected at 4.1% to 4.6%.

The organic figure excludes the Paragon 28 acquisition, which added roughly 110 basis points through its one-year anniversary.

Management discusses the quarter and the raised outlook on its investor call Wednesday at 8:30 a.m. ET.

Sources